 Eduardo Davila
Concepts (282)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Melanoma | 8 | 2025 | 757 | 2.440 |
Why?
| | Interleukin-1 Receptor-Associated Kinases | 4 | 2025 | 40 | 2.320 |
Why?
| | T-Lymphocytes | 13 | 2026 | 1984 | 1.970 |
Why?
| | CD8-Positive T-Lymphocytes | 10 | 2025 | 915 | 1.900 |
Why?
| | Antigens, Neoplasm | 5 | 2024 | 272 | 1.730 |
Why?
| | Receptors, Antigen, T-Cell | 4 | 2026 | 667 | 1.530 |
Why?
| | Myeloid Differentiation Factor 88 | 9 | 2026 | 117 | 1.450 |
Why?
| | Neoplasms | 9 | 2025 | 2873 | 1.390 |
Why?
| | Signal Transduction | 9 | 2026 | 5185 | 1.200 |
Why?
| | Immunity, Innate | 2 | 2025 | 843 | 1.190 |
Why?
| | Toll-Like Receptors | 5 | 2013 | 193 | 1.100 |
Why?
| | Immunotherapy, Adoptive | 8 | 2026 | 339 | 1.080 |
Why?
| | Toll-Like Receptor 2 | 4 | 2016 | 127 | 1.080 |
Why?
| | Melanoma, Experimental | 5 | 2016 | 109 | 1.060 |
Why?
| | Protein Tyrosine Phosphatase, Non-Receptor Type 22 | 1 | 2025 | 48 | 0.910 |
Why?
| | Immunotherapy | 5 | 2021 | 662 | 0.900 |
Why?
| | Chromones | 3 | 2024 | 42 | 0.890 |
Why?
| | DNA-Activated Protein Kinase | 1 | 2024 | 14 | 0.870 |
Why?
| | Morpholines | 3 | 2024 | 129 | 0.840 |
Why?
| | Protein Kinase Inhibitors | 4 | 2024 | 971 | 0.770 |
Why?
| | Tumor Microenvironment | 5 | 2025 | 729 | 0.760 |
Why?
| | Gene Expression Regulation, Neoplastic | 5 | 2025 | 1437 | 0.720 |
Why?
| | Cancer Vaccines | 2 | 2019 | 160 | 0.710 |
Why?
| | Apoptosis | 6 | 2020 | 2397 | 0.700 |
Why?
| | Mice | 26 | 2026 | 18261 | 0.690 |
Why?
| | Cell Line, Tumor | 10 | 2026 | 3523 | 0.690 |
Why?
| | Cell Engineering | 1 | 2021 | 14 | 0.680 |
Why?
| | Hematologic Neoplasms | 1 | 2023 | 163 | 0.680 |
Why?
| | Animals | 34 | 2026 | 37948 | 0.670 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 5 | 2025 | 1961 | 0.660 |
Why?
| | Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2025 | 26 | 0.650 |
Why?
| | Lymphocyte Activation | 10 | 2025 | 1124 | 0.640 |
Why?
| | Caspase 3 | 1 | 2020 | 234 | 0.590 |
Why?
| | Antineoplastic Agents | 4 | 2015 | 2201 | 0.580 |
Why?
| | CD8 Antigens | 2 | 2017 | 70 | 0.580 |
Why?
| | Calcium-Binding Proteins | 1 | 2020 | 222 | 0.570 |
Why?
| | Leukemia, Myeloid, Acute | 2 | 2023 | 685 | 0.560 |
Why?
| | Dendritic Cells | 2 | 2019 | 498 | 0.560 |
Why?
| | Mice, Inbred NOD | 7 | 2025 | 610 | 0.540 |
Why?
| | Phenylurea Compounds | 2 | 2017 | 113 | 0.520 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2020 | 454 | 0.510 |
Why?
| | T-Lymphocyte Subsets | 5 | 2021 | 412 | 0.500 |
Why?
| | Mice, SCID | 6 | 2025 | 368 | 0.500 |
Why?
| | Lymphoma, T-Cell | 2 | 2020 | 29 | 0.490 |
Why?
| | Toll-Like Receptor 1 | 1 | 2016 | 13 | 0.490 |
Why?
| | Tumor Necrosis Factor Receptor Superfamily, Member 9 | 1 | 2016 | 23 | 0.480 |
Why?
| | Genetic Variation | 1 | 2021 | 985 | 0.470 |
Why?
| | Gamma Rays | 2 | 2023 | 56 | 0.460 |
Why?
| | T-Lymphocytes, Cytotoxic | 2 | 2008 | 177 | 0.440 |
Why?
| | Flagellin | 1 | 2015 | 19 | 0.440 |
Why?
| | Myeloid-Derived Suppressor Cells | 3 | 2023 | 70 | 0.440 |
Why?
| | Xenograft Model Antitumor Assays | 6 | 2025 | 925 | 0.440 |
Why?
| | Recombinant Fusion Proteins | 1 | 2017 | 667 | 0.430 |
Why?
| | CD3 Complex | 2 | 2026 | 111 | 0.400 |
Why?
| | Benzimidazoles | 1 | 2015 | 187 | 0.400 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 2 | 2025 | 152 | 0.390 |
Why?
| | CD4-Positive T-Lymphocytes | 6 | 2019 | 1129 | 0.390 |
Why?
| | Antibodies, Monoclonal | 4 | 2012 | 1505 | 0.380 |
Why?
| | Cytotoxicity, Immunologic | 4 | 2017 | 221 | 0.380 |
Why?
| | Neoplasm Proteins | 3 | 2024 | 441 | 0.380 |
Why?
| | Pyridines | 1 | 2017 | 603 | 0.380 |
Why?
| | Cell Proliferation | 7 | 2020 | 2489 | 0.380 |
Why?
| | Oligodeoxyribonucleotides | 2 | 2003 | 140 | 0.370 |
Why?
| | Humans | 36 | 2026 | 144667 | 0.340 |
Why?
| | Leukemia, T-Cell | 1 | 2011 | 5 | 0.340 |
Why?
| | Mice, Knockout | 5 | 2024 | 3109 | 0.300 |
Why?
| | Adoptive Transfer | 2 | 2008 | 197 | 0.280 |
Why?
| | Cell Survival | 5 | 2017 | 1092 | 0.280 |
Why?
| | B7-H1 Antigen | 3 | 2020 | 242 | 0.280 |
Why?
| | Thymoma | 2 | 2010 | 37 | 0.270 |
Why?
| | Toll-Like Receptor 9 | 1 | 2007 | 37 | 0.260 |
Why?
| | CTLA-4 Antigen | 2 | 2025 | 105 | 0.260 |
Why?
| | Response Elements | 1 | 2007 | 85 | 0.260 |
Why?
| | Mice, Inbred C57BL | 7 | 2019 | 5967 | 0.260 |
Why?
| | Cell Movement | 2 | 2025 | 959 | 0.250 |
Why?
| | Myeloid Cell Leukemia Sequence 1 Protein | 2 | 2017 | 39 | 0.240 |
Why?
| | Immunomodulation | 2 | 2017 | 98 | 0.230 |
Why?
| | Papio | 1 | 2006 | 69 | 0.230 |
Why?
| | Protein Kinases | 1 | 2007 | 314 | 0.230 |
Why?
| | Receptors, Pattern Recognition | 1 | 2025 | 12 | 0.230 |
Why?
| | Transplantation, Heterologous | 1 | 2006 | 169 | 0.230 |
Why?
| | Membrane Glycoproteins | 2 | 2025 | 496 | 0.220 |
Why?
| | Antigens, CD | 3 | 2021 | 552 | 0.220 |
Why?
| | CD47 Antigen | 1 | 2025 | 42 | 0.220 |
Why?
| | Diphtheria Toxin | 1 | 2025 | 65 | 0.220 |
Why?
| | Immunotoxins | 1 | 2025 | 55 | 0.210 |
Why?
| | Gene Expression Profiling | 3 | 2018 | 1766 | 0.210 |
Why?
| | Neoplasm Metastasis | 2 | 2025 | 691 | 0.210 |
Why?
| | Lymphoma, T-Cell, Peripheral | 1 | 2024 | 20 | 0.200 |
Why?
| | Protein Binding | 3 | 2021 | 2243 | 0.200 |
Why?
| | Immunodominant Epitopes | 1 | 2003 | 27 | 0.200 |
Why?
| | Antigens, Differentiation | 1 | 2003 | 76 | 0.190 |
Why?
| | Intramolecular Oxidoreductases | 1 | 2003 | 65 | 0.190 |
Why?
| | Swine | 1 | 2006 | 828 | 0.190 |
Why?
| | Cell- and Tissue-Based Therapy | 1 | 2023 | 78 | 0.190 |
Why?
| | CpG Islands | 1 | 2003 | 161 | 0.190 |
Why?
| | Sarcoma | 1 | 2025 | 203 | 0.190 |
Why?
| | Dinucleoside Phosphates | 1 | 2002 | 31 | 0.190 |
Why?
| | Mice, Transgenic | 3 | 2025 | 2184 | 0.180 |
Why?
| | T-Lymphocytes, Regulatory | 1 | 2005 | 394 | 0.180 |
Why?
| | Neoplasms, Second Primary | 1 | 2023 | 101 | 0.180 |
Why?
| | Cell Communication | 2 | 2019 | 325 | 0.180 |
Why?
| | Adjuvants, Immunologic | 1 | 2003 | 245 | 0.170 |
Why?
| | Immunoconjugates | 1 | 2003 | 138 | 0.170 |
Why?
| | Antigen Presentation | 2 | 2017 | 206 | 0.170 |
Why?
| | Skin Neoplasms | 1 | 2008 | 850 | 0.160 |
Why?
| | Genetic Engineering | 1 | 2021 | 89 | 0.160 |
Why?
| | Heterografts | 1 | 2021 | 143 | 0.160 |
Why?
| | Semaphorins | 1 | 2021 | 37 | 0.160 |
Why?
| | Protein Interaction Domains and Motifs | 1 | 2021 | 146 | 0.160 |
Why?
| | Immunologic Memory | 1 | 2002 | 366 | 0.160 |
Why?
| | Disease Models, Animal | 3 | 2021 | 4539 | 0.160 |
Why?
| | Structure-Activity Relationship | 1 | 2021 | 564 | 0.150 |
Why?
| | Multiprotein Complexes | 1 | 2021 | 171 | 0.150 |
Why?
| | Immune System | 1 | 2021 | 178 | 0.150 |
Why?
| | Disease Susceptibility | 1 | 2021 | 342 | 0.150 |
Why?
| | Heart Transplantation | 1 | 2006 | 674 | 0.150 |
Why?
| | Heterocyclic Compounds, 3-Ring | 1 | 2019 | 44 | 0.150 |
Why?
| | Cytokines | 3 | 2012 | 2045 | 0.150 |
Why?
| | Carcinoma, Lewis Lung | 1 | 2019 | 16 | 0.140 |
Why?
| | Antilymphocyte Serum | 1 | 2019 | 56 | 0.140 |
Why?
| | Wnt Signaling Pathway | 1 | 2021 | 210 | 0.140 |
Why?
| | Tumor Cells, Cultured | 1 | 2020 | 881 | 0.140 |
Why?
| | Leukemia | 1 | 2021 | 245 | 0.140 |
Why?
| | HLA-A2 Antigen | 2 | 2010 | 35 | 0.140 |
Why?
| | Hematopoietic Stem Cell Transplantation | 2 | 2021 | 677 | 0.140 |
Why?
| | Proto-Oncogene Proteins c-pim-1 | 1 | 2017 | 2 | 0.130 |
Why?
| | Transplantation Tolerance | 1 | 2018 | 37 | 0.130 |
Why?
| | Jurkat Cells | 2 | 2015 | 114 | 0.130 |
Why?
| | Cells, Cultured | 3 | 2019 | 4110 | 0.130 |
Why?
| | CD55 Antigens | 1 | 2017 | 28 | 0.130 |
Why?
| | Gene Duplication | 1 | 2017 | 67 | 0.130 |
Why?
| | fms-Like Tyrosine Kinase 3 | 1 | 2017 | 50 | 0.130 |
Why?
| | Genes, MHC Class I | 1 | 2017 | 37 | 0.130 |
Why?
| | 5'-Nucleotidase | 1 | 2017 | 49 | 0.130 |
Why?
| | DNA-Binding Proteins | 1 | 2024 | 1484 | 0.130 |
Why?
| | Receptors, Virus | 1 | 2017 | 96 | 0.130 |
Why?
| | Carrier Proteins | 1 | 2021 | 733 | 0.120 |
Why?
| | Disease Management | 1 | 2021 | 650 | 0.120 |
Why?
| | Arthritis, Rheumatoid | 1 | 2005 | 1170 | 0.120 |
Why?
| | Head and Neck Neoplasms | 1 | 2021 | 562 | 0.120 |
Why?
| | Cell Transformation, Neoplastic | 1 | 2018 | 337 | 0.110 |
Why?
| | TNF Receptor-Associated Factor 6 | 1 | 2015 | 5 | 0.110 |
Why?
| | Toll-Like Receptor 5 | 1 | 2015 | 18 | 0.110 |
Why?
| | Immune Tolerance | 1 | 2017 | 381 | 0.110 |
Why?
| | Nitrophenols | 1 | 2015 | 30 | 0.110 |
Why?
| | Antigens | 2 | 2007 | 347 | 0.110 |
Why?
| | MCF-7 Cells | 1 | 2015 | 132 | 0.110 |
Why?
| | Biphenyl Compounds | 1 | 2015 | 66 | 0.110 |
Why?
| | Neoplasm Transplantation | 1 | 2015 | 246 | 0.110 |
Why?
| | Vaccination | 1 | 2003 | 1419 | 0.110 |
Why?
| | Female | 11 | 2025 | 78304 | 0.110 |
Why?
| | Vincristine | 1 | 2015 | 140 | 0.100 |
Why?
| | Protein Stability | 1 | 2015 | 177 | 0.100 |
Why?
| | Drug Synergism | 1 | 2015 | 352 | 0.100 |
Why?
| | Interferon-gamma | 2 | 2010 | 781 | 0.100 |
Why?
| | Histocompatibility Antigens Class I | 1 | 2015 | 202 | 0.100 |
Why?
| | Flow Cytometry | 1 | 2017 | 1154 | 0.100 |
Why?
| | Antifreeze Proteins | 1 | 2013 | 1 | 0.100 |
Why?
| | Gadus morhua | 1 | 2013 | 1 | 0.100 |
Why?
| | Histocompatibility Antigens Class II | 1 | 2015 | 365 | 0.100 |
Why?
| | Fish Proteins | 1 | 2013 | 12 | 0.100 |
Why?
| | Glioma | 1 | 2018 | 429 | 0.100 |
Why?
| | Galectin 3 | 1 | 2013 | 20 | 0.100 |
Why?
| | Antibody-Dependent Cell Cytotoxicity | 1 | 2012 | 21 | 0.090 |
Why?
| | Receptors, Antigen | 1 | 2012 | 14 | 0.090 |
Why?
| | Cell Growth Processes | 1 | 2012 | 47 | 0.090 |
Why?
| | HEK293 Cells | 1 | 2015 | 743 | 0.090 |
Why?
| | Piperazines | 1 | 2015 | 378 | 0.090 |
Why?
| | Weight Reduction Programs | 1 | 2013 | 138 | 0.090 |
Why?
| | Male | 8 | 2025 | 72431 | 0.090 |
Why?
| | Recombinant Proteins | 1 | 2015 | 1363 | 0.090 |
Why?
| | Promoter Regions, Genetic | 1 | 2016 | 1246 | 0.090 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2016 | 1207 | 0.080 |
Why?
| | High-Throughput Screening Assays | 1 | 2013 | 176 | 0.080 |
Why?
| | Gene Expression | 1 | 2016 | 1476 | 0.080 |
Why?
| | Transcriptome | 1 | 2018 | 1036 | 0.080 |
Why?
| | Lymphocytes | 1 | 2013 | 379 | 0.080 |
Why?
| | Receptors, Tumor Necrosis Factor, Member 14 | 1 | 2011 | 5 | 0.080 |
Why?
| | Enzyme Activation | 1 | 2012 | 762 | 0.080 |
Why?
| | Sulfonamides | 1 | 2015 | 579 | 0.080 |
Why?
| | Mobile Applications | 1 | 2013 | 197 | 0.080 |
Why?
| | Perforin | 1 | 2010 | 21 | 0.080 |
Why?
| | Social Media | 1 | 2013 | 167 | 0.080 |
Why?
| | Behavior Therapy | 1 | 2013 | 300 | 0.080 |
Why?
| | Granzymes | 1 | 2010 | 48 | 0.080 |
Why?
| | Down-Regulation | 2 | 2019 | 616 | 0.080 |
Why?
| | Mutation | 1 | 2021 | 4081 | 0.080 |
Why?
| | T-Box Domain Proteins | 1 | 2010 | 106 | 0.080 |
Why?
| | Killer Cells, Natural | 1 | 2013 | 470 | 0.080 |
Why?
| | Biomarkers | 1 | 2021 | 4261 | 0.080 |
Why?
| | Receptors, Immunologic | 1 | 2011 | 206 | 0.080 |
Why?
| | Protein Kinase C | 1 | 2010 | 250 | 0.070 |
Why?
| | Graft vs Host Disease | 1 | 2011 | 263 | 0.070 |
Why?
| | Brain Neoplasms | 1 | 2018 | 1327 | 0.070 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2010 | 380 | 0.070 |
Why?
| | Phosphorylation | 1 | 2012 | 1704 | 0.070 |
Why?
| | Transcription Factors | 1 | 2016 | 1726 | 0.070 |
Why?
| | Checkpoint Kinase 2 | 1 | 2007 | 27 | 0.070 |
Why?
| | Checkpoint Kinase 1 | 1 | 2007 | 27 | 0.070 |
Why?
| | Antibodies, Monoclonal, Humanized | 2 | 2025 | 990 | 0.070 |
Why?
| | Clinical Trials as Topic | 1 | 2013 | 1056 | 0.070 |
Why?
| | Whole-Body Irradiation | 1 | 2007 | 73 | 0.070 |
Why?
| | DNA Breaks, Double-Stranded | 1 | 2007 | 56 | 0.060 |
Why?
| | Radiation Tolerance | 1 | 2007 | 103 | 0.060 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2010 | 452 | 0.060 |
Why?
| | Adenocarcinoma | 1 | 2013 | 923 | 0.060 |
Why?
| | Ligands | 1 | 2007 | 662 | 0.060 |
Why?
| | Antibodies, Monoclonal, Murine-Derived | 1 | 2006 | 97 | 0.060 |
Why?
| | Prostatic Neoplasms | 1 | 2013 | 978 | 0.060 |
Why?
| | B7-2 Antigen | 1 | 2005 | 27 | 0.060 |
Why?
| | CD56 Antigen | 1 | 2005 | 35 | 0.060 |
Why?
| | CD28 Antigens | 1 | 2005 | 58 | 0.060 |
Why?
| | DNA Repair | 1 | 2007 | 256 | 0.060 |
Why?
| | Animals, Genetically Modified | 1 | 2006 | 245 | 0.050 |
Why?
| | Antigen-Presenting Cells | 1 | 2005 | 159 | 0.050 |
Why?
| | Clone Cells | 1 | 2005 | 263 | 0.050 |
Why?
| | Rituximab | 1 | 2006 | 211 | 0.050 |
Why?
| | Cell Cycle | 1 | 2007 | 595 | 0.050 |
Why?
| | Synovial Membrane | 1 | 2005 | 124 | 0.050 |
Why?
| | Immunophenotyping | 1 | 2005 | 318 | 0.050 |
Why?
| | Abatacept | 1 | 2003 | 56 | 0.050 |
Why?
| | Thymus Neoplasms | 1 | 2003 | 30 | 0.050 |
Why?
| | Programmed Cell Death 1 Receptor | 1 | 2025 | 264 | 0.050 |
Why?
| | Vaccines, Subunit | 1 | 2003 | 53 | 0.050 |
Why?
| | Disease Progression | 1 | 2011 | 2847 | 0.050 |
Why?
| | Doxorubicin | 1 | 2025 | 398 | 0.050 |
Why?
| | CD4 Antigens | 1 | 2003 | 137 | 0.050 |
Why?
| | Lymphocyte Count | 1 | 2002 | 164 | 0.050 |
Why?
| | Graft Rejection | 1 | 2006 | 512 | 0.050 |
Why?
| | Tretinoin | 1 | 2023 | 124 | 0.040 |
Why?
| | Chimerism | 1 | 2021 | 34 | 0.040 |
Why?
| | Graft vs Tumor Effect | 1 | 2021 | 8 | 0.040 |
Why?
| | Gene Expression Regulation | 1 | 2010 | 2591 | 0.040 |
Why?
| | Lymphocyte Subsets | 1 | 2021 | 79 | 0.040 |
Why?
| | Lymphoid Tissue | 1 | 2021 | 78 | 0.040 |
Why?
| | Obesity | 1 | 2013 | 3070 | 0.040 |
Why?
| | Fibroblasts | 1 | 2005 | 1019 | 0.040 |
Why?
| | Transplantation, Homologous | 1 | 2021 | 407 | 0.040 |
Why?
| | Cell Line | 1 | 2005 | 2821 | 0.040 |
Why?
| | Endothelial Cells | 1 | 2006 | 864 | 0.040 |
Why?
| | Amino Acid Sequence | 1 | 2003 | 2136 | 0.040 |
Why?
| | L-Selectin | 1 | 2019 | 27 | 0.040 |
Why?
| | Receptors, CCR7 | 1 | 2019 | 31 | 0.040 |
Why?
| | Base Sequence | 1 | 2002 | 2177 | 0.040 |
Why?
| | Molecular Sequence Data | 1 | 2003 | 2909 | 0.040 |
Why?
| | Benzothiazoles | 1 | 2017 | 39 | 0.030 |
Why?
| | Membrane Potential, Mitochondrial | 1 | 2017 | 74 | 0.030 |
Why?
| | Proteolysis | 1 | 2017 | 170 | 0.030 |
Why?
| | Species Specificity | 1 | 2018 | 573 | 0.030 |
Why?
| | Dogs | 1 | 2018 | 438 | 0.030 |
Why?
| | Protein Processing, Post-Translational | 1 | 2017 | 466 | 0.030 |
Why?
| | Reactive Oxygen Species | 1 | 2017 | 601 | 0.030 |
Why?
| | Computers, Handheld | 1 | 2013 | 26 | 0.020 |
Why?
| | Immunomagnetic Separation | 1 | 2013 | 4 | 0.020 |
Why?
| | Centrifugation, Density Gradient | 1 | 2013 | 36 | 0.020 |
Why?
| | Electronic Mail | 1 | 2013 | 59 | 0.020 |
Why?
| | HT29 Cells | 1 | 2013 | 37 | 0.020 |
Why?
| | Antigens, Tumor-Associated, Carbohydrate | 1 | 2013 | 8 | 0.020 |
Why?
| | Waist Circumference | 1 | 2013 | 141 | 0.020 |
Why?
| | K562 Cells | 1 | 2013 | 93 | 0.020 |
Why?
| | Aged | 2 | 2025 | 25955 | 0.020 |
Why?
| | Computational Biology | 1 | 2018 | 681 | 0.020 |
Why?
| | Cell Phone | 1 | 2013 | 82 | 0.020 |
Why?
| | Proteome | 1 | 2017 | 515 | 0.020 |
Why?
| | Phenotype | 1 | 2021 | 3147 | 0.020 |
Why?
| | Human Umbilical Vein Endothelial Cells | 1 | 2013 | 106 | 0.020 |
Why?
| | Neovascularization, Pathologic | 1 | 2013 | 284 | 0.020 |
Why?
| | Universities | 1 | 2013 | 452 | 0.020 |
Why?
| | Middle Aged | 2 | 2025 | 35971 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 2018 | 3414 | 0.020 |
Why?
| | Body Weight | 1 | 2013 | 968 | 0.020 |
Why?
| | Social Support | 1 | 2013 | 650 | 0.020 |
Why?
| | Rats | 1 | 2018 | 5570 | 0.020 |
Why?
| | Overweight | 1 | 2013 | 606 | 0.020 |
Why?
| | Students | 1 | 2013 | 657 | 0.020 |
Why?
| | Health Behavior | 1 | 2013 | 786 | 0.020 |
Why?
| | Adult | 2 | 2025 | 40489 | 0.020 |
Why?
| | Body Mass Index | 1 | 2013 | 2419 | 0.010 |
Why?
| | Cell Lineage | 1 | 2004 | 376 | 0.010 |
Why?
| | Young Adult | 1 | 2013 | 14122 | 0.010 |
Why?
| | Adolescent | 1 | 2013 | 22409 | 0.010 |
Why?
|
|
Davila's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|